Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.–10. rezultāts no 100.
51. lappuse
... active ingredients offered over - the - counter ( OTC ) for certain uses . ( a ) A number of active ingredients have been present in OTC drug prod- ucts for various uses , as described below . However , based on evidence cur- rently ...
... active ingredients offered over - the - counter ( OTC ) for certain uses . ( a ) A number of active ingredients have been present in OTC drug prod- ucts for various uses , as described below . However , based on evidence cur- rently ...
67. lappuse
... active ingredients , the drug's pharmacological class , the structural formula of the drug ( if known ) , the formulation of the dosage form ( s ) to be used , the route of admin- istration , and the broad objectives and planned ...
... active ingredients , the drug's pharmacological class , the structural formula of the drug ( if known ) , the formulation of the dosage form ( s ) to be used , the route of admin- istration , and the broad objectives and planned ...
70. lappuse
... active drug component . However , if any component in such combination is subject to an approved marketing application or is otherwise lawfully marketed in the United States , the sponsor is not re- quired to submit published material ...
... active drug component . However , if any component in such combination is subject to an approved marketing application or is otherwise lawfully marketed in the United States , the sponsor is not re- quired to submit published material ...
117. lappuse
... active in- gredient ( s ) is absorbed or otherwise made available to the site of action is less than that of the reference listed drug ; or ( 2 ) The rate at which its active ingre- dient ( s ) is absorbed or otherwise made available to ...
... active in- gredient ( s ) is absorbed or otherwise made available to the site of action is less than that of the reference listed drug ; or ( 2 ) The rate at which its active ingre- dient ( s ) is absorbed or otherwise made available to ...
130. lappuse
... active ingredient ( s ) , dosage form , strength , route of administra- tion , and conditions of use , except that ... active ingredient is sub- stituted for one of the active ingredi- ents in a listed combination drug , must first ...
... active ingredient ( s ) , dosage form , strength , route of administra- tion , and conditions of use , except that ... active ingredient is sub- stituted for one of the active ingredi- ents in a listed combination drug , must first ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning